ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

Biology Societies Endorse Cloning Prohibition Act.

February 1, 2002

Drug Approvals: FDA Approves Vectibix in mCRC With KRAS Companion Diagnostic

May 30, 2014

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

June 25, 2010

Urgent FDA Action Turns Power Morcellation Into Rarely Used Gynecological Procedure

November 26, 2014

In Brief: UICC Honors Center Director’s Efforts To Improve Cancer Control In India

March 13, 1998

NSABP’s Pink Sheet; Fisher’s Control Had A Downside, Review Said

June 24, 1994